Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery

Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy characterized by the proliferation and accumulation of mature CD5+ B cells in the peripheral blood (PB), bone marrow (BM) and lymphoid tissues. When the number of CD5+ B cells is lower than 5 × 108 cells/L, this entity is called monoclonal...

Descripción completa

Detalles Bibliográficos
Autores: Playa-Albinyana, Heribert, Arenas Ríos, Fabián, Colomer Pujol, Dolors
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2021
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/223474
Acceso en línea:https://hdl.handle.net/2445/223474
Access Level:acceso abierto
Palabra clave:Leucèmia limfocítica crònica
Ratolins transgènics
Chronic lymphocytic leukemia
Transgenic mice
id ES_bfbba1bc29c3afee165f1cf8af8a82c3
oai_identifier_str oai:diposit.ub.edu:2445/223474
network_acronym_str ES
network_name_str España
repository_id_str
spelling Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discoveryPlaya-Albinyana, HeribertArenas Ríos, FabiánColomer Pujol, DolorsLeucèmia limfocítica crònicaRatolins transgènicsChronic lymphocytic leukemiaTransgenic miceChronic lymphocytic leukemia (CLL) is a lymphoid malignancy characterized by the proliferation and accumulation of mature CD5+ B cells in the peripheral blood (PB), bone marrow (BM) and lymphoid tissues. When the number of CD5+ B cells is lower than 5 × 108 cells/L, this entity is called monoclonal B lymphocytosis (MBL) and it is asymptomatic monoclonal or oligoclonal proliferation of B cells [Citation1]. The disease may have a stable course but also become aggressive, with frequent relapses, or even transform into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL) (Richter transformation). Two major molecular subgroups have been identified: those harboring unmutated immunoglobulin heavy-chain variable region (IGHV) genes (U-CLL, ≥98% identity with the germline) and those with mutated IGHV genes (M-CLL). Genomic and epigenomic studies have elucidated multiple aspects of the pathogenesis of the disease. Nowadays CLL should be considered as a complex disease in which genetic and epigenetic mechanisms cooperate with microenvironmental factors in the malignant transformation and in leukemia progression [Citation2]. In parallel, new targeted therapies and management strategies have been developed. Due to this complexity and heterogenousity, the generation of adequate pre-clinical mouse model fully reflecting tumor biology has not yet been successfully achieved. Here we describe and discuss the mouse models developed for CLL, the most prevalent type of leukemia in adults in Western countries.Informa Healthcare2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://hdl.handle.net/2445/223474Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésVersió postprint del document publicat a: https://doi.org/10.1080/17460441.2021.1935860Expert Opinion on Drug Discovery, 2021, vol. 16, num.10, p. 1085-1090https://doi.org/10.1080/17460441.2021.1935860(c) Informa Healthcare, 2021info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/2234742026-05-27T06:46:51Z
dc.title.none.fl_str_mv Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
title Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
spellingShingle Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
Playa-Albinyana, Heribert
Leucèmia limfocítica crònica
Ratolins transgènics
Chronic lymphocytic leukemia
Transgenic mice
title_short Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
title_full Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
title_fullStr Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
title_full_unstemmed Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
title_sort Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery
dc.creator.none.fl_str_mv Playa-Albinyana, Heribert
Arenas Ríos, Fabián
Colomer Pujol, Dolors
author Playa-Albinyana, Heribert
author_facet Playa-Albinyana, Heribert
Arenas Ríos, Fabián
Colomer Pujol, Dolors
author_role author
author2 Arenas Ríos, Fabián
Colomer Pujol, Dolors
author2_role author
author
dc.subject.none.fl_str_mv Leucèmia limfocítica crònica
Ratolins transgènics
Chronic lymphocytic leukemia
Transgenic mice
topic Leucèmia limfocítica crònica
Ratolins transgènics
Chronic lymphocytic leukemia
Transgenic mice
description Chronic lymphocytic leukemia (CLL) is a lymphoid malignancy characterized by the proliferation and accumulation of mature CD5+ B cells in the peripheral blood (PB), bone marrow (BM) and lymphoid tissues. When the number of CD5+ B cells is lower than 5 × 108 cells/L, this entity is called monoclonal B lymphocytosis (MBL) and it is asymptomatic monoclonal or oligoclonal proliferation of B cells [Citation1]. The disease may have a stable course but also become aggressive, with frequent relapses, or even transform into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL) (Richter transformation). Two major molecular subgroups have been identified: those harboring unmutated immunoglobulin heavy-chain variable region (IGHV) genes (U-CLL, ≥98% identity with the germline) and those with mutated IGHV genes (M-CLL). Genomic and epigenomic studies have elucidated multiple aspects of the pathogenesis of the disease. Nowadays CLL should be considered as a complex disease in which genetic and epigenetic mechanisms cooperate with microenvironmental factors in the malignant transformation and in leukemia progression [Citation2]. In parallel, new targeted therapies and management strategies have been developed. Due to this complexity and heterogenousity, the generation of adequate pre-clinical mouse model fully reflecting tumor biology has not yet been successfully achieved. Here we describe and discuss the mouse models developed for CLL, the most prevalent type of leukemia in adults in Western countries.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/223474
url https://hdl.handle.net/2445/223474
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1080/17460441.2021.1935860
Expert Opinion on Drug Discovery, 2021, vol. 16, num.10, p. 1085-1090
https://doi.org/10.1080/17460441.2021.1935860
dc.rights.none.fl_str_mv (c) Informa Healthcare, 2021
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Informa Healthcare, 2021
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418416945758208
score 15.811543

Similares en LA Referencia